Characteristics of High-Cost Beneficiaries of Prescription Drugs in Kazakhstan: A Cross-Sectional Study of Outpatient Data from 2022
There is a concentration of public drug program spending within a small percentage of beneficiaries with high drug costs in Kazakhstan. This discovery offers valuable insights for shaping policies tailored to this specific population, aiming to mitigate escalating costs and enhance the optimal use of medications.
Authors
- Bibigul Omirbayeva (ORCID: https://orcid.org/0000-0002-5154-4943)
- Ardak Nurbakyt (ORCID: https://orcid.org/0000-0002-4854-6809)
- Lyazzat Kosherbayeva (ORCID: https://orcid.org/0000-0001-8376-4345)
- Anuar Akhmetzhan (ORCID: https://orcid.org/0009-0009-7451-9706)
- Adilet Nazarbayev
Institutions
- Al-Farabi Kazakh National University (KZ)
- Kazakh National Medical University (KZ)
- National Research Center for Maternal and Child Health (KZ)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/ceor.s470632
- Citations
- 3
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.39